ACM
ADAP

Aquatic Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Aquatic Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,100
Closed -$1K – 1310
2022
Q3 		$1K Buy
+1,100
New +$2.02K ﹤0.01% 1120
2022
Q2 		– Sell
-1,600
Closed -$3K – 1147
2022
Q1 		$3K Buy
+1,600
New +$4.32K ﹤0.01% 890

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Aquatic Capital Management's ADAP Position: Q4 2022 in Review

Aquatic Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2022, closing a stake of 1,100 shares — an estimated $1K sold.

Aquatic Capital Management first reported a position in ADAP in Q1 2022 and held it in 2 quarters. The position peaked at $3K in Q1 2022. 69 funds tracked by Wall St. Rank hold ADAP as of Q4 2022.

  • Aquatic Capital Management reported no remaining Adaptimmune Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Aquatic Capital Management sold 1,100 Adaptimmune Therapeutics shares in Q4 2022, an estimated $1K.
  • Aquatic Capital Management first reported a position in Adaptimmune Therapeutics in Q1 2022 and held it in 2 quarters.
  • Aquatic Capital Management's Adaptimmune Therapeutics position peaked at $3K in Q1 2022.
  • 69 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2022.

Based on Aquatic Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.